Navigation Links
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
Date:11/21/2011

CAMBRIDGE, England, November 21, 2011 /PRNewswire/ --

Phase I Single Dose Study Data Demonstrate Ideal Pharmacokinetic Profile and Excellent Safety and Tolerability

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines, today announces that the multiple ascending dose Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated.

The trial is a randomised, placebo controlled Phase I study to investigate the pharmacokinetics, safety and tolerability of orally administered multiple dose regimens of CNV2197944 in both young and elderly volunteers. CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis. The study is expected to conclude in 2Q 2012.

The first human single ascending dose Phase I study with orally administered CNV2197944 was recently completed. CNV2197944 was shown to be well absorbed, with an ideal pharmacokinetic profile for the target indication of chronic pain. The compound was well tolerated, with an excellent safety profile.

Clive Dix, Chief Executive Officer of Convergence Pharmaceuticals, commented: "We are really excited to be advancing on schedule to a multiple ascending dose study with this novel, first-in-class treatment for chronic pain.  The data we have seen so far gives us great confidence that CNV2197944 will be a safe and effective long term treatment for chronic pain."

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Convergence Pharmaceuticals Announces Start of Phase II Study for its Selective Nav 1.7 blocker CNV1014802
2. Nano-Bio-Info-Cogno Revolutions to be Explored at Convergence08 Unconference - Forecaster Paul Saffo to Keynote
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Access Pharmaceuticals Signs Agreement for CobaCyte® and CobOral® in RNAi Therapeutic Delivery
5. Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders
6. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Credit Suisse Healthcare Conference on November 9, 2011
9. Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2011 Financial Results and Recent Operational Highlights
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... About Bioactive Material Bioactive ... are increasingly becoming popular due to their ability ... having a negative impact on the human health. ... tissue repair materials in surgical procedures. Bioactive materials ... glass-ceramics, and composites. The major end-users of bioactive ...
(Date:9/23/2014)... France (PRWEB) September 23, 2014 ... of laboratory personnel since 1968 and Burdinola, supplier of ... of a new filtered fume hood. , ... laboratory fume hood, Burdinola will now offer an innovative ... a wide range of chemicals, best-in-class detection technology, and ...
(Date:9/23/2014)... ATCC, the premier global biological materials resource and ... to the senior leadership team. Barbie Bigelow has joined ... and Dr. Maryellen de Mars also joins as the ... are new positions at ATCC. , ... described the additions as part of a revitalization strategy ...
(Date:9/23/2014)... September 23, 2014 Follow ... gaining steady popularity the world over, due to ... Growth in the marketplace is expected to come ... in developing countries. Several sub-Saharan countries in the ... have already implemented genetically engineered crop production strategies. ...
Breaking Biology Technology:Global Bioactive Material Market 2014-2018 2Erlab Partners with Burdinola to Deliver an Innovative Filtered Fume Hood 2ATCC Announces New Appointments to its Leadership Team 2ATCC Announces New Appointments to its Leadership Team 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Rising Focus on Food Security Spurs Growth in the Global Agricultural Biotechnology Market, According to New Report by Global Industry Analysts, Inc. 4
... MILWAUKEE Catalyst International, a global provider of ... suite of platform-independent SCE applications. , ,"We're expanding ... customers' increasing demand for integrated fulfillment solutions from ... boundaries," said Jim Treleaven, President and CEO of ...
... WAUKESHA, WI. - RedPrairie Corporation , has ... electronic product code (EPC)-compliant radio frequency identification ... in a real-world environment. The RFID Lab is ... tag placement and readability as they prepare for ...
... supports plans for growth and strategic investments , ... and services company, today announced it has signed a ... Merchants and Manufacturers BanCorp (MMBC) , a Milwaukee-based ... credit, from which no monies have been drawn, was ...
Cached Biology Technology:RedPrairie Builds RFID Lab - Enables Real-World Testing 2
(Date:9/22/2014)... University researchers are studying a potential new treatment that ... in which scars develop in the lungs and severely ... miR-29, which is delivered to lung tissue intravenously. In ... reversed fibrosis after several days. , The findings ... Molecular Medicine . , "The mimic, when injected into ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
(Date:9/22/2014)... Antarctic fishes that manufacture their own "antifreeze" ... also suffer an unfortunate side effect, researchers report: ... bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences . ... undesirable consequence of the evolution of antifreeze proteins ...
Breaking Biology News(10 mins):Reversing the effects of pulmonary fibrosis 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3
... HOLLYWOOD, Calif., Aug. 20, 2012 (Pinksheets: MDBX) ( www.medboxinc.com ... 2nd quarter 2012 financials, which showed earnings of over $820,000 ... has almost doubled since the beginning of the year, and ... Medbox earns all its revenue through consulting services and the ...
... Southampton and the National Oceanography Centre, Southampton has found ... increase the bleaching susceptibility of reef corals. Corals ... a layer of living tissue covering the calcareous skeletons. ... within the coral polyps. The coral animal ...
... effort at Arizona State University to educate and train ... by the National Science Foundation (NSF). Through its Integrative ... is providing $3 million to ASU to help develop ... with the skills needed to find solutions to the ...
Cached Biology News:Medbox, Inc. Releases 2nd Quarter Financials 2Improving water quality can help save coral reefs 2ASU awarded $3 million to research solar energy technologies, launch energy Ph.D. program 2
... a partial recombinant IFNA2. Immunogen: ... is produced in E. coli. The biological ... OMIM: 147562, ... MM951100564 MA Code: ABV0P9DPB ...
Mouse monoclonal antibody raised against a partial recombinant STAU2. NCBI Entrez Gene ID = STAU2...
Mouse polyclonal antibody to NR2F2 - nuclear receptor subfamily 2, group F, member 2...
Mouse monoclonal antibody raised against a full length recombinant YARS. NCBI Entrez Gene ID = YARS...
Biology Products: